UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 12b-25
 
 
 
NOTIFICATION OF LATE FILING
OMB APPROVAL
OMB Number: 3235-0058
Expires: August 31, 2015
Estimated average burden
hours per response......2.50
 
SEC FILE NUMBER
000-53231
 
(Check one): ¨    Form 10-K     o    Form 20-F     o    Form 11-K      x    Form 10-Q    o    Form 10-D     o    Form N-SAR     o    Form N-CSR
CUSIP NUMBER
     
 
For Period Ended: March 31, 2014
   
 
o Transition Report on Form 10-K
   
 
o Transition Report on Form 20-F
   
 
o Transition Report on Form 11-K
   
 
o Transition Report on Form 10-Q
   
 
o Transition Report on Form N-SAR
   
 
For the Transition Period Ended: ____________________
 
 
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
PART I — REGISTRANT INFORMATION

HUBEI MINKANG PHARMACEUTICAL LTD.
 
Full Name of Registrant
 
   
 
 
Former Name if Applicable
 
   
55 Ubi Ave. 3, #03-01, Mintwell Building
 
Address of Principal Executive Office (Street and Number)
 
   
Singapore 408864
 
City, State and Zip Code
 
 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
     
x
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
     
 
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE
 
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.
 
HUBEI MINKANG PHARMACEUTICAL LTD. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2014 (the “Quarterly Report”) by the May 15, 2014 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Quarterly Report. As a result, the Registrant is still in the process of compiling required information to complete the Quarterly Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the period ended March 31, 2014 to be incorporated in the Quarterly Report. The Registrant anticipates that it will file the Quarterly Report no later than the fifth calendar day following the prescribed filing date.
 
SEC 1344 (04-09)
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
 
(Attach extra Sheets if Needed)
 
PART IV — OTHER INFORMATION
 
(1)
Name and telephone number of person to contact in regard to this notification
   
 
Lee Tong Tai
 
(65 )
 
6747-7883
 
(Name)
 
(Area Code)
 
(Telephone Number)
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
Yes x      No  o
   
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
Yes  o      No x
   
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
2
 
 
HUBEI MINKANG PHARMACEUTICAL LTD.
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: May 16, 2014
By:
/s/ Lee Tong Tai
 
   
Lee Tong Tai
President, Chief Executive Officer and
Chief Financial Officer
 
 
 
 
3
Hubei Minkang Pharmaceut... (GM) (USOTC:HBMK)
Historical Stock Chart
From May 2024 to May 2024 Click Here for more Hubei Minkang Pharmaceut... (GM) Charts.
Hubei Minkang Pharmaceut... (GM) (USOTC:HBMK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Hubei Minkang Pharmaceut... (GM) Charts.